Agios Pharmaceuticals Inc (AGIO)
43.11
-0.50
(-1.15%)
USD |
NASDAQ |
Jun 28, 16:00
43.03
-0.08
(-0.19%)
After-Hours: 20:00
Agios Pharmaceuticals SG&A Expense (Annual): 119.90M for Dec. 31, 2023
SG&A Expense (Annual) Chart
Historical SG&A Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 119.90M |
| December 31, 2022 | 121.67M |
| December 31, 2021 | 121.44M |
| December 31, 2020 | 115.10M |
| December 31, 2019 | 102.01M |
| December 31, 2018 | 114.14M |
| December 31, 2017 | 71.12M |
| Date | Value |
|---|---|
| December 31, 2016 | 50.71M |
| December 31, 2015 | 35.99M |
| December 31, 2014 | 19.12M |
| December 31, 2013 | 9.929M |
| December 31, 2012 | 7.064M |
| December 31, 2011 | 7.215M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Annual) Range, Past 5 Years
102.01M
Minimum
2019
121.67M
Maximum
2022
116.03M
Average
119.90M
Median
2023
SG&A Expense (Annual) Benchmarks
| Arcutis Biotherapeutics Inc | 185.14M |
| Insmed Inc | 344.50M |
| Krystal Biotech Inc | 98.40M |
| Arvinas Inc | 100.30M |
| BridgeBio Pharma Inc | 150.59M |